Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cannovex BV currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct art unit. The prosecution involves the distinct examiner ARNOLD, ERNST V, who is also the busiest examiner in the portfolio. The busiest examiner is responsible for the pending office action. This singular focus indicates that the current prosecution activity is concentrated under the examiner and art unit mentioned.
The Biotechnology & Pharmaceuticals designation suggests that the pending matter involves complex biological or medicinal subject matter. Having the prosecution handled by ARNOLD, ERNST V allows for a consistent dialogue between the applicant and the USPTO. This streamlined interaction can be beneficial for maintaining a clear record during the examination process. The lack of other pending actions means that the legal team can dedicate their full attention to this specific case. Practitioners should monitor the specific art unit for any unique procedural requirements that might affect the outcome. The role of ARNOLD, ERNST V is pivotal in navigating the current requirements for the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002189 | PULMONARY FORMULATION COMPRISING CANNABINOIDS | ARNOLD, ERNST V | 52d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18002189 | PULMONARY FORMULATION COMPRISING CANNABINOIDS | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | 52d overdue | Pending | Jul 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial